Files

Chaccour_C_Trials_2020.pdf (444.54 KB)

Document type

Article

Version

Published version

Publication date

2020-06-08

Publication license

cc by (c) Chaccour et al., 2020
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/174448

The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

http://dx.doi.org/10.1186/s13063-020-04421-z

Abstract

Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment.

Subject

SARS-CoV-2, Medicaments antivírics

Subject (English)

SARS-CoV-2, Antiviral agents

Citation

Collections

Articles publicats en revistes (ISGlobal)

Citation

CHACCOUR, Carlos, et al. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to
                Evaluate the Potential of Ivermectin to Reduce COVID-19
                Transmission in low risk, non-severe COVID-19 patients in the
                first 48 hours after symptoms onset: A structured summary of a
                study protocol for a randomized control pilot trial. Trials. 2020. Vol. 21. ISSN 1745-6215. [consulted: 18 of June of 2026]. Available at: https://hdl.handle.net/2445/174448

Export metadata

JSON - METS

Share record